CLINICAL REVIEW

Gastrointestinal Manifestations of Pediatric Coronavirus Disease and Their Relationship with a Severe Clinical Course: A Systematic Review and Meta-analysis

Rishi Bolia MD, DM,1 Akhil Dhanesh Goel MD,2* Mayank Badkur MS,3 and Vidhi Jain MD4

1Division of Paediatric Gastroenterology, Department of Paediatrics, All India Institute of Medical Sciences, Rishikesh, Uttarakhand 249201, India
2Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan 342005, India
3Department of General Surgery, All India Institute of Medical Sciences, Jodhpur, Rajasthan 342005, India
4Department of Microbiology, All India Institute of Medical Sciences, Jodhpur, Rajasthan 342005, India
*Correspondence: Akhil Dhanesh Goel, Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, C214, Academic Block, Jodhpur, Rajasthan 342005, India. E-mail <doc.akhilgoel@gmail.com>.

ABSTRACT

Background: Data on the gastrointestinal (GI) manifestations of Pediatric Corona Virus Disease (COVID-19) are conflicting and the relationship between GI involvement and the severity of COVID-19 disease has not been evaluated. The objectives of this systematic review were to determine the GI manifestations of pediatric COVID-19 and to evaluate their role as risk factors for a severe clinical course.

Methods: A systematic literature search was carried out in PubMed and Scopus for studies published before 31 December 2020 with information about the GI manifestations of pediatric COVID-19. Patients with a severe and nonsevere clinical course were compared using the inverse variance heterogeneity model and odds ratio (OR) as the effect size. A sensitivity analysis was performed if the heterogeneity was high among studies.

Results: A total of 811 studies were identified through a systematic search of which 55 studies (4369 patients) were included in this systematic review. The commonest GI symptoms were diarrhea—19.08% [95% confidence interval (CI) 10.6–28.2], nausea/vomiting 19.7% (95% CI 7.8–33.2) and abdominal pain 20.3% (95% CI 3.7–40.4). The presence of diarrhea was significantly associated with a severe clinical course with a pooled OR of 3.97 (95% CI 1.80–8.73; p < 0.01). Abdominal pain and nausea/vomiting were not associated with disease severity.

© The Author(s) [2021]. Published by Oxford University Press. All rights reserved.
For permissions, please email: journals.permissions@oup.com
Conclusions: Diarrhea, nausea/vomiting or abdominal pain are present in nearly one-fifth of all children with COVID-19. The presence of diarrhea portends a severe clinical course.

KEYWORDS: diarrhea, nausea, abdominal pain, SARS-CoV-2

INTRODUCTION

Children account for 1–3% of the cases of coronavirus disease 2019 (COVID-19) reported around the world [1]. Pediatric symptoms are variable and a tetrad of cough, fever, dyspnea and malaise are the most commonly reported symptoms. However, apart from the respiratory system, COVID-19 impacts other systems, of which gastrointestinal manifestations are the commonest [2].

Recognizing the GI symptoms of COVID-19 in children is important as they have GI manifestations more often than adults do [3]. GI symptoms may be the sole presenting symptoms of COVID-19 in a child. They may precede respiratory symptoms or may manifest later during the disease course. Pooled analyses which included patients reported till April 2020 showed that gastrointestinal manifestations are quite common in pediatric COVID-19, with nearly 25% exhibiting at least one GI symptom. The commonly reported symptoms being diarrhea, nausea/vomiting and abdominal pain [4].

With the recognition of multisystem inflammatory syndrome (MIS-C), a manifestation of pediatric COVID-19 characterized by intense systemic inflammation and multiorgan failure, GI symptoms have been further highlighted in the pediatric age group. Radia et al. [5] in a meta-analysis of 735 individual cases of MIS-C found that 71% had GI symptoms. MIS-C was first reported in early May, and there is a need for updated data on the GI manifestations of COVID-19 that accounts for these children as well.

Available data suggest that an asymptomatic or mild disease course is more common in the pediatric age group as compared to adults. However, severe cases and deaths do occur in children too and have been reported worldwide. In a pooled analysis of 27 studies (4857 patients), 4% children had severe disease [2]. A young age and the presence of underlying comorbidities have been documented as risk factors for a severe disease course in children [1]. In adults, the presence of GI symptoms has also been correlated with increased odds of critical disease [6].

However, in the pediatric age group, it is unclear whether the presence of gastrointestinal symptoms also portends a severe disease course.

Hence, this meta-analysis was conducted to evaluate the frequency of GI symptoms in pediatric COVID-19 and to figure out whether they were a risk factor for the severe clinical course of the disease.

METHODS

This systematic review and meta-analysis have been performed using the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA).

Criteria for considering the studies for review

Inclusion and exclusion of studies were planned using the PECO format—Participants, Exposure group, Control group and Outcomes. Participants included all children (<19 years) with COVID-19. A COVID-19 diagnosis was considered in children who either had a positive real-time polymerase chain reaction (RT-PCR) for SARS-CoV-2 in the nasopharyngeal swab or had compatible clinical symptoms with the presence of a positive ELISA IgG or IgM for SARS-CoV-2. Exposure group was cases of pediatric COVID-19 with gastrointestinal manifestations. Controls were children with COVID-19 without gastrointestinal manifestations. Outcome studied was children with a severe clinical course that was determined using any one of the following criteria:

- patients requiring pediatric intensive care unit (PICU) care
- patients developing organ dysfunction
- patients who have been categorized to have severe/critical disease according to standard criteria [7]
- patients who did not survive

Search strategy

A literature search was carried out systematically with no time or language restrictions using the electronic databases—PubMed and Scopus for keywords...
related to the inclusion criteria to identify relevant cohort or cross-sectional studies. The references of the included studies were also reviewed manually to ensure the inclusion of all pertinent articles. The detailed search strategy has been described in Supplementary Table S1.

Last search for articles was performed on 31st December 2020.

Data extraction
Three reviewers independently extracted data using a predetermined criterion. The following data were extracted from each study: number of patients, study setting, demographic data, gastrointestinal manifestations and number of patients having a severe and non-severe clinical course. Any discrepancy in data extraction was resolved by mutual discussion.

Quality assessment
The studies reporting the prevalence data were evaluated by the Appraisal tool for Cross-Sectional Studies (AXIS). This tool comprises of a total of 20 items evaluating the various aspects of the methodological quality of the studies pertaining to aims/objectives, study design, sample size, reference population, representativeness, non-response, appropriateness and validity of risk and outcome variables, approach to statistical significance, completeness of methodology, description and internal consistency of data, synchrony between the methods, results, discussion and conclusion, description of limitation of the study, potential conflicts of interest and adherence to ethical principles. Each item is rated by three options: ‘Yes’ (Y)—when it meets the description of the evaluation criterion, ‘no’ (N)—when the particular criterion is not met or ‘Unclear’ (U)—when there is insufficient information to evaluate a particular criterion [8].

The quality of the studies included in the comparative data analysis was evaluated by the Joanna Briggs Institute (JBI) critical appraisal checklist. The risk of bias was assessed through 10 questions that evaluated the comparability of groups, matching, criteria for identifying the groups, validity of measurement tools, uniformity in exposure assessment, approach to confounder identification, appropriateness of length of exposure and appropriateness of statistical analysis used [9]. Individual questions were assessed as Yes, No or Unclear.

Statistical analysis
The inverse variance heterogeneity model has been utilized for ascertaining the summary effect in this meta-analysis. The pooled prevalence of the individual gastrointestinal symptoms—diarrhea, nausea/vomiting, abdominal pain, dysgeusia and anorexia were expressed as proportion and [95% confidence interval (CI)]. The data were presented in a forest plot. The risk of occurrence of gastrointestinal symptoms in patients with severe as compared to non-severe disease course were described using odds ratios (OR). Heterogeneity between studies was assessed using I^2 values. I^2 values of more than 75% would indicate high heterogeneity. A p value of less than 0.05 was considered statistically significant. Further, sensitivity analysis was performed by excluding each study to investigate the effect on the overall pooled prevalence and heterogeneity. Poor quality and outlier studies were considered for exclusion in sensitivity analysis. Small-study effects, which may be due to a publication bias, were investigated by the Luis Furuya Kanamori (LFK) index and DOI plot. A value of LFK index <1 is indicative of no symmetry, between 1 and 2 indicates minor symmetry and more than 2 is indicative of major asymmetry. Meta-analysis was performed using MetaXL softwarev5.3 software (EpiGear International, Sunrise Beach, Australia).

RESULTS
A total of 811 records were found using the systematic search strategy. After removing 143 duplicate studies, 668 articles were screened by title and abstract and were excluded if they were not about the COVID-19 (n = 6), did not involve patients in the pediatric age group (n = 131), did not contain information about the gastrointestinal manifestations of COVID-19 (n = 215), were case reports (n = 126), were review articles (n = 129), was a study protocol only (n = 4), was an erratum (n = 1) or did not involve human subjects (n = 1). The selection strategy followed is summarized in Fig. 1.

Finally, 55 studies were selected for inclusion in this systematic review [10–64]. Seven studies had data comparing severe with nonsevere disease course
and were included in the meta-analysis evaluating the association of GI symptoms with the severity of the disease course.

Study characteristics
The characteristics of the 55 studies that were included in the final analysis are summarized in
| First author       | Country     | Study design | n   | Mean age (months) | Gender (male) | Fever | Respiratory symptoms | Diarrhea | Nausea/vomiting | Abdominal pain | Severe | Non-severe |
|-------------------|-------------|--------------|-----|-------------------|---------------|-------|----------------------|----------|-----------------|----------------|--------|-----------|
| Gonzalez Jimenez  | Spain       | Retrospective| 101 | 112.8             | 58            | 82    | 60                   | 33       | 35              | 35             | 30     | 71        |
| Garcia-Salido     | Spain       | Prospective  | 71  | 97.2              | 45            | 61    | 23                   | 33       | 38/40          | 45             | 0      | 0         |
| Esmaeili Dooki    | Iran        | Retrospective| 18  | 82.44             | 12            | 16    | 6                    | 7        | 6               |               | –      | –         |
| Zhang             | China       | Retrospective| 41  | 71.16             | 23            | 24    | 8                    | 2        | 0               | 0              | 41     | 0         |
| Giacomet          | Italy       | Retrospective| 127 | 57.6              | 83            | 105   | 82                   | 28       | 12              | 8              | 20     | 107       |
| Al-Omari          | Saudi Arabia| Prospective  | 16  | 126              | 15            | 6     | 4                    | 2        | 0               | 0              | 16     | 0         |
| Song              | USA         | Retrospective| 54  | 99.6              | 25            | 41    | 24                   | –        | –               | –              | 18     | 36        |
| Storch-de-Gracia  | Spain       | Retrospective| 39  | 108              | 23            | 32    | 17                   | 14       | 15              | 12             | 15     | 24        |
| Mamishi           | Iran        | Retrospective| 45  | 84              | 23            | 41    | 16                   | 16       | 23              | 26             | 14     | 31        |
| Godfred-Cato      | USA         | Retrospective| 570 | 96              | 359           | 303   | 352                  | 353      | 364             | 206            | –      | –         |
| Adedeji           | Nigeria     | Prospective  | 53  | 12.63             | 28            | 9     | 11                   | 5        | 3               | 4              | 0      | 51        |
| Li                | Singapore   | Retrospective| 39  | 96              | 23            | 13    | 4                    | 3        | 0               | 0              | 0      | 39        |
| Blumfield         | USA         | Retrospective| 19  | 96              | 10            | 17    | 13                   | 9        | –               | 2              | 14     | 5         |
| Davies            | UK          | Retrospective| 78  | 132             | 52            | 78    | –                    | 50       | 49              | 48             | 78     | 0         |
| Xiong             | China       | Retrospective| 244 | 82              | 150           | 99    | 120                  | 15       | 23              | 4              | 3      | 241       |
| Zhang             | China       | Retrospective| 34  | 33              | 14            | 26    | 21                   | 4        | 4               | –              | 0      | 34        |
| Kaushik           | USA         | Retrospective| 33  | 120             | 20            | 31    | 11                   | 16       | 23              | 21             | 33     | 0         |
| Miller            | USA         | Retrospective| 44  | 87.6             | 20            | 44    | 11                   | 18       | 25              | 33             | 44     | 0         |
| Tullie            | UK          | Retrospective| 8   | 138             | 5             | 8     | 0                    | 8        | 8               | 8              | –      | –         |
| Garazzino         | Italy       | Retrospective| 168 | 27.6            | 94            | 138   | 82                   | 22       | 9               | 0              | 2      | 166       |
| Tan               | China       | Retrospective| 10  | 84              | 3            | 4     | 2                    | 0        | 1               | 1              | 0      | 10        |
| Shen              | China       | Retrospective| 9   | 96              | 3            | 4     | 1                    | 2        | –               | –              | 0      | 9         |
| Wang              | China       | Retrospective| 31  | 85              | –            | 20    | 14                   | 3        | –               | –              | 0      | –         |
| Tan               | China       | Retrospective| 13  | 96              | 4            | 6     | 7                    | 2        | 1               | 1              | 1      | 12        |
| Pereira           | Brazil      | Retrospective| 66  | 117.5           | 33            | 53    | 30                   | –        | –               | –              | 26     | 40        |
| Qiu               | China       | Retrospective| 36  | 99.6           | 23            | 13    | 7                    | –        | –               | –              | 0      | 36        |
| Xia               | China       | Retrospective| 20  | 25.5           | 13            | 12    | 13                   | 3        | 2               | –              | 0      | 20        |
| Whittaker         | UK          | Retrospective| 58  | 108           | 25            | 12    | 30                   | 26       | 31              | 29             | 29     | 29        |
| Liu               | China       | Retrospective| 6   | 36              | 2            | 6     | 6                    | –        | 4               | –              | 1      | 5         |

(continued)
| First author | Country | Study design | n   | Mean age (months) | Gender (male) | Fever | Upper respiratory symptoms | Diarrhea | Nausea/vomiting | Abdominal pain | Severe | Non-severe |
|--------------|---------|--------------|-----|-------------------|---------------|-------|-----------------------------|----------|-----------------|----------------|--------|-----------|
| Sun          | China   | Retrospective | 8   | 80                | 6             | 6     | 6                           | 3        | 4               | 0              | 8      | 0         |
| Zachariah    | USA     | Retrospective | 50  | 138               | 27            | 40    | 23                          | –        | –               | –              | 9      | 41        |
| Du           | China   | Retrospective | 14  | 74                | 6             | 5     | 3                           | 0        | 0               | 0              | 0      | –         |
| Song         | China   | Retrospective | 16  | 102               | 10            | 5     | 6                           | 0        | 0               | 0              | 0      | 0         |
| Chen         | China   | Retrospective | 12  | 174               | 6             | 7     | 7                           | 4        | –               | –              | 0      | 12        |
| Du           | China   | Retrospective | 182 | 72                | 120           | 79    | 81                          | 9        | 7               | 7              | 4      | 178       |
| Parri        | Italy   | Retrospective | 130 | 72                | 73            | 67    | 54                          | 10       | 15              | –              | 9      | 121       |
| Mithal       | USA     | Retrospective | 10  | 2                 | 7             | 9     | 8                           | 4        | 3               | –              | –      | –         |
| Xiong        | China   | Retrospective | 244 | 14                | 19            | 99    | 14                          | 15       | 23              | 4              | –      | –         |
| Derespina    | USA     | Retrospective | 70  | 180               | 43            | 85    | 84                          | 30       | 44              | –              | 21     | 49        |
| Zhang        | China   | Retrospective | 46  | 96                | 29            | 10    | 15                          | 0        | 0               | 0              | –      | –         |
| Chen         | China   | Retrospective | 32  | 114               | 21            | 20    | 10                          | 6        | –               | –              | 0      | 32        |
| Mahmoudi     | Iran    | Retrospective | 35  | 90                | 22            | 27    | 28                          | 9        | 10              | 4              | 14     | –         |
| Brisca       | Italy   | Retrospective | 24  | 82.8              | –             | 20    | 18                          | 3        | 2               | –              | –      | –         |
| Mamishi      | Iran    | Retrospective | 24  | 82.8              | 11            | 24    | 15                          | 3        | 5               | 5              | 17     | 6         |
| Parri        | Italy   | Retrospective | 170 | 45                | 95            | 82    | 73                          | 19       | 24              | 13             | –      | –         |
| Shahbaznejad| Iran    | Retrospective | 19  | 64                | 6             | 8     | 8                           | 7        | 6               | 0              | –      | –         |
| El Fakiri    | Morocco | Retrospective | 74  | 84                | 34            | 8     | 5                           | 4        | –               | –              | 0      | 74        |
| Guo          | China   | Retrospective | 80  | 72                | 52            | 38    | 39                          | 6        | –               | –              | –      | 80        |
| Krasnova     | Russia  | Prospective   | 218 |                   |               | 218   | 43                          | 39       | 14              | –              | –      | –         |
| Sarangi      | India   | Retrospective | 50  | 72                | 28            | 17    | 15                          | 2        | –               | –              | 0      | –         |
| Chua         | China, Hong Kong, South Korea | Prospective | 423 | 100.4             | 254           | 145   | 239                         | 34       | 7               | 12             | 0      | –         |
| Cairoli      | Argentina | Retrospective | 191 | 92.4             | 103           | 55    | 54                          | 6        | –               | –              | 0      | –         |
| Leibowitz    | USA     | Retrospective | 20  | 1                 | 19            | –     | 4                           | 4        | 4               | –              | –      | –         |
| Hosseninasab | Iran    | Retrospective | 13  | 60                | 9             | 11    | 13                          | –        | –               | –              | 0      | –         |
| Popova       | Russia  | Retrospective | 36  | –                 | –             | –     | –                           | 23       | –               | 21             | –      | –         |
Table 1. Twenty-three of the studies were multicentric while the rest (n = 32) of the studies were from single centers. Most were from China (20/55, 36.3%) followed by those from USA (10/55, 18%), Italy (5/55, 9%) and Iran (5/55, 9%). This review included 4369 patients [median 41 (6–570) patients per study] and 1829 were males. MIS-C was the diagnosis in 886 (20.2%).

**Risk of bias assessment**

The risk of bias assessment of the included studies has been summarized in Supplementary Tables S2 and S3.

**Gastrointestinal symptoms**

The pooled prevalence of diarrhea was 19.08% (95% CI 10.6–28.2%) (Fig. 2). These data were obtained from 49 studies comprising 4008 children. A high degree of heterogeneity (I² = 95%) was found which could not be eliminated on sensitivity analysis.

The pooled prevalence of nausea/vomiting (40 studies, 3480 patients, Fig. 3) and abdominal pain (31 studies, 2518 patients, Fig. 4) was 19.7% (95% CI 7.8–33.2%) and 20.3% (95% CI 3.7–40.4%), respectively. The I² statistic for these respective symptoms was 97% and 98%.

Other GI symptoms were recorded only in a handful of the studies. Data regarding anorexia/feeding difficulties were available in seven studies with a pooled prevalence of 10% (95% CI 0–26%), I² = 95%, while dysgeusia was reported in only four studies and had a prevalence of 3% (95% CI 0–7%), I² = 66%.

**Gastrointestinal symptoms and their association with a severe clinical course**

Information regarding the clinical course (severe vs non-severe) was given in 37 studies which included 2670 (848 severe, 1822 non-severe) patients. Seven studies assessed the association of diarrhea with a severe disease course. It was found that it was significantly associated with the severity of the clinical course of the disease with an OR of 3.97 (95% CI 1.80–8.73; p < 0.01) (Fig. 5A). There was nonsignificant heterogeneity among studies with an I² of 48%. There was no asymmetry for small-study effects (LFK index = -0.28, Supplementary Fig. S1a).

Nausea and vomiting as a risk factor for a severe disease were assessed in six studies. No association was found between its presence and the severity of the disease (OR 2.59, 95% CI 0.79–8.44) (Fig. 5B). There was significant heterogeneity amongst studies (I² = 78%) which persisted even after a sensitivity analysis. There was no asymmetry for small-study effects (LFK index = 0.68, Supplementary Fig. 1b).

Similarly, abdominal pain which was assessed in four studies was not found to be a risk factor for severe disease (OR 0.34, 95% CI 0.076–1.55) (Fig. 5C). There was no asymmetry for small-study effects (LFK index = 0.78, Supplementary Fig. 1c).

**DISCUSSION**

This is the first meta-analyses in children studying the gastrointestinal manifestations of COVID-19 and their association with the severity of the clinical course of the disease. To sum up the results, abdominal pain was the commonest gastrointestinal symptom seen in 20% children, followed by nausea and/or vomiting in 19.7%, and diarrhea in 19%. The presence of diarrhea was a risk factor for a severe clinical course (OR 3.97) but not nausea/vomiting or abdominal pain.

The entry of SARS-CoV-2 into the host cells is facilitated by the angiotensin-converting enzyme-2 (ACE2) which is considered as a receptor for the virus. Apart from the respiratory tract, these receptors are also present in the GI tract and in individuals affected by SARS-CoV-2 the presence of the viral RNA has been demonstrated in almost the entirety of the GI tract. The viral RNA has also been demonstrated in the stools of patients of COVID-19 and it has been shown that the fecal RT-PCR may continue to be positive even after respiratory viral shedding ceases [65]. The passage of SARS-CoV-2 in stool and its ability to survive in sewage water is a public health concern [66]. While feco-oral virus transmission has been suggested [67], its persistence in polluted water bodies may result in further mutations within the SARS-CoV-2 genome, though not as frequently as the antigenic shifts and drifts seen in influenza.

The GI symptoms of SARS-CoV-2 may be caused either by a direct invasion of the virus or by immune-mediated tissue injury. When the ACE2-
Fig. 2. Prevalence of diarrhea in children with COVID-19.
Fig. 3. Prevalence of nausea/vomiting in children with COVID-19.
expressing enterocytes are infected by the virus, it may lead to mucosal inflammation, malabsorption and unbalanced intestinal secretion causing diarrhea. This was demonstrated by Effenberger et al. [68] when they showed that SARS-CoV-2 infection prompted an inflammatory response in the gut, as evidenced by elevated levels of serum IL-6 and fecal calprotectin.

In the first few published series of COVID-19 patients, the proportion of patients with GI symptoms was low. However, with the spread of the pandemic, this prevalence has increased, probably owing to increasing awareness about the nonrespiratory symptoms of the disease among clinicians. The first meta-analysis of the GI manifestations of COVID-19 in children was performed by Akobeng et al. They analyzed nine studies (published till 1 April 2020), comprising 280 patients and found that the pooled prevalence of diarrhea, vomiting and abdominal pain was 12.4%, 10.3% and 5.4%, respectively [4]. Subsequently, Wang et al. [69] carried out a meta-analysis of GI symptoms in children in which

![Fig. 4. Prevalence of abdominal pain in children with COVID-19.](https://academic.oup.com/tropej/article/67/2/fmab051/6288463)
studies published till 10 August 2020 were included. Their analysis included 38 studies (3028 patients) and they found that the total incidence of GI symptoms was 17.7%. The pooled prevalence of the individual symptoms was not assessed in this study. We included 55 studies published till 31st December 2020 and found that the gastrointestinal symptoms of abdominal pain, nausea/vomiting and diarrhea

Fig. 5. Forest plot showing pooled odds ratio of (A). Diarrhea being associated with severe clinical course. (B) Nausea/vomiting being associated with severe clinical course. (C) Abdominal being associated with severe clinical course.
were found in nearly one-fifth of all children with COVID-19, suggesting a steady rise in the incidence of reported GI symptoms in children over time.

Xu et al. [70] demonstrated that the GI tissues had a relatively higher ACE2 expression compared to the pulmonary tissues, with their expression in the lungs increasing with age. These data may explain the differences in the symptoms of COVID-19 between children and adults, with gastrointestinal symptoms being more common in children and its respiratory manifestations being more common in adults. In various meta-analyses containing mainly adult patients, the pooled estimates of the prevalence of diarrhea, nausea/vomiting and abdominal pain have been reported to range from 7.4–9.1%, 4.6–7.8% and 2.7–3.5%, respectively suggesting that these GI symptoms are less common in adults as compared to children [6, 71–73]. This is in contradiction to the report by Mao et al. who had reported a similar frequency of GI symptoms in children and adults in a meta-analysis of 35 studies (till 10 April 2020). However, their analysis included only 266 children (vs. 6402 adult patients). Moreover, it did not include children with MIS-C which was first reported in early May [5].

The current literature suggests that children with COVID-19 fare better than adults and are relatively spared from developing severe disease manifestations. The factors that potentially protect children from developing severe COVID-19 disease are—the absence of comorbidities, a good regenerative capacity of the lung and lack of immune senescence [74]. The presence of a strong innate immune response as a result of frequent viral infections during childhood has also been postulated as a protective factor. Though relatively uncommon, severe clinical manifestations do occur in a small proportion of children, and it is important to try and identify the risk factors for the same. Studies in adults have suggested that GI symptoms play a role in the overall picture of the disease with those having GI symptoms having a more severe clinical course. Mao et al. in a meta-analysis of 6 studies (2014 patients) of whom 247 had gastrointestinal involvement found that those with GI symptoms had an increased risk of a severe clinical course with an OR of 3.97. They found that patients with severe manifestations of COVID-19 had a higher likelihood for abdominal pain as a symptom when compared to those without a severe clinical course [6]. The prognosis of children with COVID-19 with GI manifestations is unclear and conflicting. Giacomet et al. in an Italian cohort of 127 children reported that GI symptoms were more frequently associated with a severe disease phenotype. Amongst the individual GI symptoms, they found that the presence of vomiting and diarrhea but not abdominal pain to correlate with disease severity [14]. Gonzalez et al. in a cohort of 101 pediatric COVID-19 patients from 15 centers across Spain found that after adjusting for the confounding factors, those with the presence of either vomiting, abdominal pain or diarrhea had a higher risk of admission to the pediatric intensive care unit. On the other hand in a study of 45 children with MIS-C neither of the individual GI symptoms portended a more severe course [18]. On a pooled analysis we found that patients with diarrhea, but not abdominal pain and nausea/vomiting correlated with disease severity.

The strength of our meta-analysis is the fact that it includes a large number of patients (55 studies including a total of 4369 patients) who hail from a diverse regional background. Information from observational studies done in 15 different countries have been included in our analysis and our results are likely a true depiction of the clinical picture of pediatric COVID-19. This is in contrast to the initial reports which consisted of data originating mainly from China. In our analysis, we have also included studies that were not in English. Google Translate®, a free, web-based program was used for the translation.

Our meta-analysis is not without limitations. Firstly, a large number of the included studies were retrospective in nature. Secondly, there was a lot of heterogeneity which could not be eliminated on sensitivity analysis. Thirdly, the aim of most of the included studies was primarily to describe the clinical profile of children with COVID-19. It is well known that respiratory symptoms are the most common symptoms of COVID-19, and hence it is possible that the GI manifestations were under-reported in them. Fourthly, as most of the studies included hospital-based data it is conceivable that our estimates represent the prevalence of gastrointestinal manifestations only in children who require hospital
admission. We excluded all studies (n = 215) that did not contain information about gastrointestinal symptoms, and the absence of information was not assumed to equate that these symptoms were absent. Lastly, the different studies included in this meta-analysis used different definitions to define severe COVID-19 which probably contributed to the heterogeneity that was observed.

To conclude, our systematic review and meta-analysis have reaffirmed the fact that GI manifestations are common in pediatric COVID-19. Our analysis suggests that the presence of diarrhea probably portends a severe clinical course and there is a need for focused attention to the care of children who have diarrhea as a symptom of COVID-19. Prospective studies are needed to confirm our findings.

SUPPLEMENTARY DATA
Supplementary data are available at Journal of Tropical Pediatrics online.

REFERENCES
1. Tsabouri S, Makis A, Kosmeri C, et al. Risk factors for severity in children with coronavirus disease 2019: a comprehensive literature review. Pediatr Clin North Am 2021; 68:321–38.
2. Meena J, Yadav J, Saini L, et al. Clinical features and outcome of SARS-CoV-2 infection in children: a systematic review and meta-analysis. Indian Pediatr 2020;57:820–6.
3. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J 2020;39:355–68.
4. Akobeng AK, Grafton-Clarke C, Abdelgadir I, et al. Gastrointestinal manifestations of COVID-19 in children: a systematic review and meta-analysis. Frontl Gastroenterol 2020;1–6, doi: 10.1136/fgastro-2020-101529.
5. Radia T, Williams N, Agrawal P, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation. Paediatr Respir Rev 2020;0542;30117–2.
6. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis [published correction appears in Lancet Gastroenterol Hepatol. 2020 Jul;5(7):e6]. Lancet Gastroenterol Hepatol 2020;5:667–78.
7. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020;145:e20200702.
8. Downes MJ, Brennan ML, Williams HC, et al. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open 2016;6: e011458.
9. Munn Z, Barker TH, Moola S, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 2020;18:2127–33.
10. Gonzalez Jimenez D, Velasco Rodriguez-Belvis M, Ferrer Gonzalez P, et al. COVID-19 gastrointestinal manifestations are independent predictors of PICU admission in hospitalized pediatric patients. Pediatr Infect Dis J 2020; 39:e459–e462.
11. Garcia-Salido A, de Carlos VJ, Belda HS, et al. Spanish Pediatric Intensive Care Society Working Group on SARS-CoV-2 Infection. Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Crit Care 2020;24:666.
12. Esmaeili Dooki M, Mehrabani S, Sorkhi H, et al. COVID-19 and digestive system in children: a retrospective study. Arch Iran Med 2020;23:782–6.
13. Zhang Y, Xie RM, He YL, et al. Clinical and imaging features of pediatric COVID-19. Ital J Pediatr 2020;46: 153.
14. Giacomelli V, Barcellini L, Stracuzzi M, COVID-19 Pediatric network, et al. Gastrointestinal symptoms in severe COVID-19 children. Pediatr Infect Dis J 2020;39: e317–e320.
15. Al-Omari A, Alhuqbani WN, Zaidi ARZ, et al. Clinical characteristics of non-intensive care unit COVID-19 patients in Saudi Arabia: a descriptive cross-sectional study. J Infect Public Health 2020;13:1639–44.
16. Song X, Delaney M, Shah RK, et al. Comparison of clinical features of COVID-19 vs seasonal influenza A and B in US children. JAMA Netw Open 2020;3:e2020495.
17. Storch-de-Gracia P, Leoz-Gordillo I, Andina D, et al. Clinical spectrum and risk factors for complicated disease course in children admitted with SARS-CoV-2 infection. An Pediatr (Engl Ed) 2020;93:323–33.
18. Mamishi S, Movahedi Z, Mohammadi M, et al. Multisystem inflammatory syndrome associated with SARS-CoV-2 infection in 45 children: a first report from Iran. Epidemiol Infect 2020;148:e196.
19. Godfred-Cato S, Bryant B, Leung J, et al.; California MIS-C Response Team. COVID-19-associated multisystem inflammatory syndrome in children - United States, March-July 2020. Morb Mortal Wkly Rep 2020;69:1074–80.
20. Adeleji IA, Abdu YM, Bashir MF, et al. Profile of children with COVID-19 infection: a cross sectional study from North-East Nigeria. Pan Afr Med J 2020;5:145.
21. Li J, Thoon KC, Chong CY, et al. Comparative analysis of symptomatic and asymptomatic SARS-CoV-2 infection in children. Ann Acad Med Singap 2020;9:530–7.
Gastrointestinal Manifestations of Pediatric Coronavirus Disease

22. Blumfield E, Levin TL. COVID-19 in pediatric patients: a case series from the Bronx, NY. Pediatr Radiol 2020;50:1369–74.

23. Davies P, Evans C, Kanthimathinathan HK, et al. Intensive care admissions of children with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health 2020;4:e669–77.

24. Xiong X, Chua GT, Chi S, et al. A Comparison between Chinese children infected with coronavirus disease-2019 with severe acute respiratory syndrome 2003. J Pediatr 2020;224:30–6.

25. Zhang C, Gu J, Chen Q, et al. Clinical and epidemiological characteristics of pediatric SARS-CoV-2 infections in China: a multicenter case series. PLoS Med 2020;17:e1003130.

26. Kaushik S, Aydin SI, Derespina KR, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2 infection (MIS-C): a Multi-institutional Study from New York City. J Pediatr 2020;224:24–9.

27. Miller J, Cantor A, Zachariah P, et al. Gastrointestinal symptoms as a major presentation component of a novel multisystem inflammatory syndrome in children that is related to coronavirus disease 2019: a single center experience of 44 cases. Gastroenterology 2020;159:1571–4.e2.

28. Tullie L, Ford K, Bisharat M, et al. Gastrointestinal features in children with COVID-19: an observation of varied presentation in eight children. Lancet Child Adolesc Health 2020;4:e19–e20.

29. Garazzino S, Montagnani C, Donà D, et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Euro Surveill 2020;25:2000600.

30. Tan YP, Tan BY, Pan J, et al. Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019 in Changsha, China. J Clin Virol 2020;127:104353.

31. Shen Q, Guo W, Guo T, et al. Novel coronavirus infection in children outside of Wuhan, China. Pediatr Pulmonol 2020;55:1424–9.

32. Wang D, Ju XL, Xie F, et al. Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China. Zhonghua Er Ke Za Zhi 2020;58:269–74.

33. Tan X, Huang J, Zhao F, et al. Clinical features of children with SARS-CoV-2 infection: an analysis of 13 cases from Changsha, China. Zhongguo Dang Dai Er Ke Za Zhi 2020;22:294–8.

34. Pereira MFB, Litvinov N, Farhat SCL, et al. Severe clinical spectrum with high mortality in pediatric patients with COVID-19 and multisystem inflammatory syndrome. Clinics (Sao Paulo) 2020;75:e2209.

35. Qiu H, Wu J, Hong L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis 2020;20:689–96.

36. Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol 2020;55:1169–74.

37. Whittaker E, Bamford A, Kenny J, et al.; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020;324:259–69.

38. Liu W, Zhang Q, Chen J, et al. Detection of Covid-19 in children in early January 2020 in Wuhan, China. N Engl J Med 2020;382:1370–1.

39. Khan M, Khan H, Khan S, et al. Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study. J Med Microbiol 2020;69:1114–23.

40. Zachariah P, Johnson CL, Halabi KC, Columbia Pediatric COVID-19 Management Group, et al. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a Children’s Hospital in New York City, New York. JAMA Pediatr 2020;174:e202430.

41. Song W, Li J, Zou N, et al. Clinical features of pediatric patients with coronavirus disease (COVID-19). J Clin Virol 2020;127:104377.

42. Chen J, Zhang ZZ, Chen YK, et al. The clinical and immunological features of pediatric COVID-19 patients in China. Genes Dis 2020;7:535–41.

43. Du H, Dong X, Zhang JJ, et al. Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status. Allergy 2021;76:510–32.

44. Parri N, Magistà AM, Marchetti F, et al.; CONFIDENCE and COVID-19 Italian Pediatric Study Networks. Characteristic of COVID-19 infection in pediatric patients: early findings from two Italian Pediatric Research Networks. Eur J Pediatr 2020;179:1315–23.

45. Mithal LB, Machut KZ, Muller WJ, et al. SARS-CoV-2 Infection in Infants Less than 90 Days Old. J Pediatr 2020;Sep224:150–2.

46. Xiong XL, Wong KK, Chi SQ, et al. Comparative study of the clinical characteristics and epidemiological trend of 244 COVID-19 infected children with or without GI symptoms. Gut 2021;70:436–8.

47. Derespina KR, Kaushik S, Plichta A, et al. Clinical manifestations and outcomes of critically ill children and adolescents with coronavirus disease 2019 in New York City. J Pediatr 2020;226:55–63.e2.

48. Zhang B, Liu S, Zhang J, et al. Children hospitalized for coronavirus disease 2019 (COVID-19): a multicenter retrospective descriptive study. J Infect 2020;81:e74–e75.
94. Chen Z, Tong L, Zhou Y, et al. Childhood COVID-19: a multicentre retrospective study. Clin Microbiol Infect 2020;26:1260.e1-1260.e4.
95. Mahmoudi S, Meh dizadeh M, Shervin Bady R, et al. The Coronavirus Disease 2019 (COVID-19) in Children: a study in an Iranian Children’s Referral Hospital. Infect Drug Resist 2020;13:2649–55.
96. Guo Y, Xia W, Peng X, et al. The early experiences of a single tertiary Italian emergency department treating COVID-19 in children. Acta Paediatr 2020;109:2155–6.
97. Mamishi S, Heydari H, Aziz-Ahari A, et al. Novel coronavirus disease 2019 (COVID-19) outbreak in children in Iran: atypical CT manifestations and mortality risk of severe COVID-19 infection. J Microbiol Immunol Infect 2020.
98. Parri N, Lenge M, Cantoni B, et al.; ON BEHALF OF THE CONFIDENCE RESEARCH GROUP. COVID-19 in 17 Italian Pediatric Emergency Departments. Pediatrics 2020;146:e20201235.
99. Shahbaznejad L, Navaeifar MR, Abbaskhanian A, et al. Clinical characteristics of 10 children with a pediatric inflammatory multisystem syndrome associated with COVID-19 in Iran. BMC Pediatr 2020;20:513.
100. Fakiri KE, Nassih H, Sab IA, et al. Epidemiology and clinical features of coronavirus disease 2019 in Moroccan children. Indian Pediatr 2020;57:808–10.
101. Guo Y, Xia W, Peng X, et al. Features discriminating COVID-19 from community-acquired pneumonia in pediatric patients. Front Pediatr 2020;8:602083.
102. Sarangi B, Reddy VS, Oswal JS, et al. Epidemiological and clinical characteristics of COVID-19 in Indian children in the initial phase of the pandemic. Indian Pediatr 2020;57:914–7.
103. Chua GT, Xiong X, Choi EH, et al. COVID-19 in children across three Asian cosmopolitan regions. Emerg Microbes Infect 2020;9:2588–96.
104. Cairoli H, Raiden S, Chiolo MJ, et al. Patients assisted at the Department of Medicine of a pediatric hospital at the beginning of the COVID-19 pandemic in Buenos Aires, Argentina. Arch Argent Pediatr 2020;118:418–26.
105. Leibowitz J, Krief W, Barone S, et al. Comparison of clinical and epidemiologic characteristics of young febrile infants with and without severe acute respiratory syndrome coronavirus-2 infection. J Pediatr 2021;229:41–7.e1.
106. Hosseninasab A, Bafti MS, Ebrahimii S, et al. Coronavirus disease 2019 in children with acute respiratory infection: a study from Southeastern Iran. Shiraz E-Med J 2020;21:e108377.
107. Popova RV, Ruzhentsova TA, Khavkina DA, et al. Gastrointestinal tract disorders in COVID-19 infected children. Problemy Osnovykh Infektsii 2020;154–7.
108. Krasnova EI, Karpovich GS, Komissarova TV, et al.; Novosibirsk State Medical University, Novosibirsk, Russia. Pediatrica - Zhurnal im G.N. Pediatria 2020;99:141–7.
109. Du W, Yu J, Wang H, et al. Clinical characteristics of COVID-19 in children compared with adults in Shandong Province, China. Infection 2020;48:445–52.
110. Galanopoulos M, Gkeros F, Doukatas A, et al. COVID-19 pandemic: pathophysiology and manifestations from the gastrointestinal tract. World J Gastroenterol 2020;26:4579–88.
111. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382:1564–7.
112. Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol 2020;5:335–7.
113. Effenerger M, Grabherr F, Mayr L, et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut 2020;69:1543–4.
114. Wang JG, Cui HR, Tang HB, et al. Gastrointestinal symptoms and fecal nucleic acid testing of children with 2019 coronavirus disease: a systematic review and meta-analysis. Sci Rep 2020;10:17846.
115. Xu J, Chu M, Zhong F, et al. Digestive symptoms of COVID-19 and expression of ACE2 in digestive tract organs. Cell Death Discov 2020;6:76.
116. Sultan S, Altayar O, Siddique SM, et al. Rapid review of the gastrointestinal and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19. Gastroenterology 2020;159:320–34.e27.
117. Parasa S, Desai M, Thoguluva Chandra sekhar V, et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: a systematic review and meta-analysis. JAMA Netw Open 2020;3:e2011335.
118. Wang H, Qiu P, Liu J, et al. The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2020;44:653–61.
119. Dhochak N, Singhal T, Kabra SK, et al. Pathophysiology of COVID-19: why children fare better than adults? Indian J Pediatr 2020;87:537–46.